Aim: Hypofunction of N-methyl-D-aspartate receptors (NMDAR) may contribute to the pathophysiology of schizophrenia (SCZ). Recently, the glycine cleavage system (GCS) was shown to affect NMDAR function in the brain. GCS functional defects cause nonketotic hyperglycinemia, the atypical phenotype of which presents psychiatric symptoms similar to SCZ. Here, we examined the involvement of GCS in SCZ.
Aim: Hypofunction of N-methyl-D-aspartate receptors (NMDAR) may contribute to the pathophysiology of schizophrenia (SCZ). Recently, the glycine cleavage system (GCS) was shown to affect NMDAR function in the brain. GCS functional defects cause nonketotic hyperglycinemia, the atypical phenotype of which presents psychiatric symptoms similar to SCZ. Here, we examined the involvement of GCS in SCZ.
Methods: First, to identify the rare variants and the exonic deletions, we resequenced all the coding exons and the splice sites of four GCS genes (GLDC, AMT, GCSH, and DLD) in 474 patients with SCZ and 475 controls and performed multiplex ligation-dependent probe amplification analysis in SCZ. Next, we performed metabolome analysis using plasma of patients harboring GCS variants (n = 5) and controls (n = 5) by capillary electrophoresis time-of-flight mass spectrometry.
The correlation between plasma metabolites and Positive and Negative Syndrome Scale score was further examined.
Results: Possibly damaging variants were observed in SCZ: A203V, S801N in GLDC, near the atypical nonketotic hyperglycinemia causative mutations (A202V, A802V); G825D in GLDC, a potential neural tube defect causative mutation; and R253X in AMT. Marked elevation of plasma 5-oxoproline (pyroglutamic acid), aspartate, and glutamate, which might affect NMDAR function, was observed in patients harboring GCS variants. The aspartate level inversely correlated with negative symptoms (r = −0.942, P = 0.0166).
Conclusion:
These results suggest that GCS rare variants possibly contribute to the pathophysiology of SCZ by affecting the negative symptoms through elevation of aspartate.
Key words: aspartate, metabolome analysis, N-methyl-D-aspartate receptor hypofunction hypothesis, rare variants, schizophrenia. S CHIZOPHRENIA (SCZ) IS a common devastating psychiatric disease with a prevalence of around 0.8% worldwide and an estimated heritability of approximately 80%.
1 Several large-scale genome-wide association studies (GWAS) have identified the common genetic variants in SCZ. 2 Identification of rare variants with possibly strong effects is another promising strategy to elucidate the pathophysiology of SCZ as the common variants identified thus far have a small effect size, from 1.1 to 1.3. [3] [4] [5] Target resequencing to identify rare variants using next-generation sequencing technology has become feasible.
Accumulating lines of evidence suggest the involvement of N-methyl-D-aspartate receptors (NMDAR) hypofunction in the pathophysiology of SCZ. [6] [7] [8] [9] The results from recent large-scale genetic studies further support this hypothesis. For example, the largest SCZ GWAS of 36 989 cases and 113 075 controls, performed by the Psychiatric Genomics Consortium, revealed that the common variants in GRIN2A and SRR reached genome-wide significance.
2 GRIN2A and SRR encode NMDA receptor subunit 2A and serine racemase, which is involved in the synthesis of D-serine, a co-agonist of NMDAR, from L-serine, 10 respectively. The largest exome study of 4877 Swedish patients with SCZ further added evidence that disruptive rare variants in NMDAR and activity-regulated cytoskeletonassociated protein complex confer the risk for SCZ by replicating the previous findings from an exome study of 2536 SCZ cases and 2543 controls. 11, 12 The function of NMDAR is strictly regulated by co-agonist, D-serine and glycine. 13, 14 The glycine cleavage system (GCS) is a main pathway for catalyzing glycine and functional defect of the GCS causes nonketotic hyperglycinemia (NKH). 15 The GCS consists of four proteins encoded by GLDC (glycine dehydrogenase, D90239), AMT (aminomethyltransferase, BC044792), GCSH (glycine cleavage system protein H, BC000790), and DLD (dihydrolipoamide dehydrogenase, AK294146). 15 Recent studies have shown that the distribution of GCS components overlaps with NMDAR in the hippocampus and cerebral cortex, indicating that the GCS may be a direct regulator of NMDAR function in the brain. 16, 17 NKH is an autosomal recessive disease and most typical NKH patients present with intractable seizures, or progressive respiratory failure, and die soon after birth. 18, 19 However, patients with atypical NKH do not show such fatal symptoms, and often become clinically apparent in adulthood due to psychiatric symptoms, such as late-onset mild mental retardation, cognitive impairment, and behavioral problems [20] [21] [22] similar to those of SCZ. Interestingly, the concentration of D-serine was shown to be remarkably reduced in the post-mortem brain of NKH patients 23 as well as in the plasma of SCZ patients. 24 The GCS is a part of one-carbon (C1) metabolism involved in homocysteine metabolism by supplying 5,10-methylenetetrahydrofolate, the substrate for 5,10-methylenetetrahydrofolate reductase (MTHFR). 15 In some patients with SCZ, the aberrant metabolism of homocysteine has been reported. [25] [26] [27] Furthermore, a genetic association between the MTHFR C677T variant and SCZ has been repeatedly confirmed. [28] [29] [30] [31] Therefore, we hypothesized that the GCS is involved in the pathophysiology of SCZ.
To examine the involvement of the GCS in SCZ, first, we tested the genetic involvement of rare single nucleotide variations (SNV), insertions and deletions, and exonic deletions of GCS genes (GLDC, AMT, GCSH, and DLD) in SCZ. Additionally, we assessed whether atypical NKH was present in patients diagnosed with SCZ. Next, we evaluated the effects of the detected rare variants by plasma metabolome analysis, and further assessed the correlation between metabolite levels and Positive and Negative Syndrome Scale (PANSS) scores in the patients.
METHODS

Subjects
For genetic analysis, 474 unrelated patients with SCZ (234 men and 240 women, age 43.12 AE 15.14 years) and 475 controls (224 men and 251 women, age 41.54 AE 12.43 years) were recruited from the Department of Neuropsychiatry, the University of Tokyo Hospital, related hospitals, and day-care facilities located around Tokyo. There were no significant differences in sex and age between the groups. The patients were diagnosed according to the DSM-IV criteria 32 by the consensus of at least two psychiatrists. Patients with a history of drug addiction and alcohol abuse/dependence were excluded. PANSS scores 33 were obtained for some patients. Control subjects with present or lifetime mental illness, alcohol abuse/dependence, or a family history of SCZ were excluded by the Mini-International Neuropsychiatric Interview 34 or an unstructured interview. All subjects were ethnically Japanese. For the metabolome analysis, five patients (two men and three women, age 50.2 AE 14.33 years) and five controls (five women, age 39.0 AE 2.28 years), whose plasma was available, were analyzed. The study was performed in accordance with the Declaration of Helsinki. The protocol for the research project was approved by the Research Ethics Committee of the Faculty of Medicine, University of Tokyo (approval No. G0639-(33)). Written informed consent was obtained from all the subjects and patient anonymity has been preserved.
Sequencing
We performed targeted resequencing of all the coding regions and the splice sites (AE5 bp) of GLDC, AMT, GCSH, and DLD to identify missense/nonsense variations and small insertions/deletions by next-generation sequencing using Illumina TruSeq Custom Amplicon on Miseq (Illumina, San Diego, CA, USA). dsDNA (250 ng) was applied according to the manufacturer's instructions. Amplicons were designed using Design Studio (http://designstudio. illumina.com/); 75 amplicons were available for the GCS genes. After hybridization, ligation, and amplification, PCR products were normalized by magnetic beads and sequenced by Miseq. Raw FASTQ files were retrieved and short reads were aligned to the hg19 reference by Burrows-Wheeler Aligner software (http://bio-bwa.sourceforge.net/). 35 Picard tools were used to remove the duplicates. SAMtools (http://samtools.sourceforge.net/) was used for conversion to BAM files and variant calling. 36 GATK was used for base quality score recalibration and detected SNV and small insertions and deletions. VCF files enabled us to extract the variants. All the missense, nonsense, and splice sites variants, as well as genomic regions of variants sequenced with lowcoverage by Miseq or with no available replicons, were directly examined by Sanger sequencing. Primers used in Sanger sequencing are described in Table S1 . Variants with minor allele frequency (MAF) ≤ 0.5% were examined in this study (Fig. 1) . We annotated as novel variants according to the Human Genetic Variation Database, Genome Aggregation Database (gnomAD; http://gnomad. broadinstitute.org/), and Tohoku University Tohoku Medical Megabank Organization (ToMMo; http:// www.megabank.tohoku.ac.jp/). To predict the function disrupted by the variations, we used dbNSFP (database for nonsynonymous SNPs' functional predictions https://sites.google.com/site/jpopgen/ dbNSFP), 37 an integrated functional prediction database of SIFT/PROVEAN, Polyphen2, LRT, Mutation Taster, and FATHMM. 37 
MLPA analysis
We examined the exonic deletions of GLDC, a major cause of NKH, 38 by MLPA analysis in 474 patients with SCZ. MLPA analysis was performed according to the manufacturer's instructions (www.mrc-holland. com), using SALSA MLPA probe mix P209-B1 GLDC (MRC-Holland, Amsterdam, the Netherlands). After hybridization, ligation, and amplification, PCR products were separated by size using a 3130xl Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). 38 For normalization, relative peak areas were calculated by dividing each measured peak area by the sum of the five control peak areas as described elsewhere 38 using Peak Scanner Software 1.0 (Thermo Fisher Scientific, http://peak-scanner-software.soft ware.informer.com/download/).
Metabolome analysis
Five SCZ patients with variants in GCS genes (GLDC T119I, A203V, V685M, S801N, and DLD P39L) and five controls were assessed in this study. Peripheral blood samples were drawn by experienced psychiatrists from a peripheral vein of subjects after they had fasted for at least 10 h. Within 30 min of blood collection, plasma samples were isolated via centrifugation at 1200 g for 10 min, and then stored at −80 C until use. Plasma samples (100 μL) were plunged into 0.45 mL methanol containing 10 μM each of internal standards methionine sulfone and 10-camphorsulfonic acid and mixed well. 39 Deionized water (200 μL) and chloroform (0.5 mL) were added, and the solution was centrifuged at 2300 g for 5 min at 4 C. The upper aqueous layer was centrifugally filtered through a 5-kDa cut-off filter (Human Metabolome Technologies, Inc., Tsuruoka, Japan). 39 Samples were applied to a capillary electrophoresis system equipped with an Agilent 6210 time-of-flight mass spectrometer (CE-TOFMS, Agilent Technologies, Santa Clara, CA, USA), as described elsewhere. 39 Metabolites were annotated by both the specific m/z value and the migration time.
Statistical analysis
Comparison of the number of observed rare variants between patients and controls was performed by Fisher's exact test. The Student's t-test was used to evaluate the levels of metabolites, and Bonferroni correction was applied to solve multiple testing problems. The correlation between each PANSS score and the level of metabolites was assessed by Pearson's correlation. All statistical tests were twotailed, and a P-value of less than 0.05 was considered significant.
RESULTS
Rare variants in SCZ
To clarify the contribution of rare variants in GCS genes to the pathophysiology of SCZ, we sequenced all of the coding regions and the splice sites of GLDC, AMT, GCSH, and DLD in 474 patients and 475 controls. We first performed the targeted resequencing, then analyzed all the detected nonsynonymous variants with MAF < 0.5% reaching a final coverage of 10. Regions with low coverage (less than 20) and with no available designed amplicons were directly sequenced by Sanger sequencing. A flowchart of the analysis is shown in Figure 1 . Eight patients and 12 controls were excluded because of DNA degradation. We identified 23 rare variants (MAF < 0.5%; missense, nonsense, and splice sites variants) in patients with SCZ and 27 variants in controls in the coding exons of GCS genes. We detected no exonic deletions of GLDC in MLPA analysis. All variants identified are shown in Table 1 and Figure 2 . Among these 50 variants, 19 were novel. The total number of rare variants predicted to affect protein function (dbNSFP score > 4.000) showed no significant difference between the groups (GLDC: P = 1.000, AMT: P = 0.419, GCSH: P = 0.624, DLD: P = 0.725). Regarding the novel rare variants predicted to affect protein function (dbNSFP score ≥ 4.000), no significant difference was observed between the groups (GLDC: P = 0.217, AMT: P = 0.249, GCSH: P = 1.000, DLD: P = 1.000).
Next, we assessed whether patients with atypical NKH were included in the patients diagnosed with SCZ. NKH and atypical NKH are reported to be autosomally recessive. 19 We cross-referenced detected variants with thus far reported typical and atypical NKH causative mutations (Fig. 2, Table S2 ), and did not observe the variants represented in any homozygous or compound heterozygous manner. The R410K variant of GLDC, which has been previously reported as a causative mutation for NKH, 40 was detected in a heterozygous manner in one patient with SCZ and in one control.
However, rare variants identified in three SCZ patients (A203V of GLDC in one patient, and S801N of GLDC in two patients) were located near the causative mutations of atypical NKH (A202V, A802V), one of which presents psychotic symptoms after early adolescence (Fig. 2) . 41, 42 The functional prediction of A203V and S801N by dbNSFP was deleterious (4.559/5, 4.573/5, respectively, Table 1 ). Further, G825D in GLDC, a possible causative mutation for neural tube defects (NTD), 43 was detected in two SCZ patients but not in controls. Nonsense variant R253X in AMT was also identified in one patient with SCZ.
Elevation of plasma 5-oxoproline (pyroglutamic acid), aspartate, and glutamate in SCZ patients with GCS variants
We performed metabolomic analysis using plasma to evaluate the effects of the rare variants by comparing five patients harboring the variants (GLDC T119I, A203V, V685M, S801N, and DLD P39L) and five controls.
Comprehensive metabolomic profiling was performed by CE-TOFMS, and the comparative value of each metabolite was assessed. We detected 170 metabolites, including 87 anions and 83 cations, as candidates. Among the 170 metabolites, 5-oxoproline (>sevenfold change, P = 9.4 × 10 ) were markedly and significantly higher in patients with SCZ harboring the variants than in controls (Fig. 3) . Methionine sulfoxide, a metabolite of C1 metabolism, 44 showed a trend of change (adjusted P = 0.0721), but other metabolites in GCS or onecarbon metabolism were not changed in this study.
Inverse correlation between plasma aspartate levels and negative symptoms
All of the significantly elevated metabolites (5-oxoproline, aspartate, and glutamate) have been shown to affect the NMDAR function. [45] [46] [47] [48] Therefore, we assessed the correlation between the level of these metabolites and PANSS score (Total, Positive, Negative, and General) in patients with GCS variants. The plasma level of aspartate showed a significant inverse correlation with the Negative Symptoms scale (r = −0.942, adjusted P = 0.0166, after Bonferroni correction, Fig. 4) . However, 5-oxoproline and glutamate did not show any significant correlation (5-oxoproline: r = −0.336, glutamate: r = 0.144). The individual items of the Negative Symptoms score also showed significant inverse correlation with aspartate, except for stereotyped thinking (Table S3) .
DISCUSSION
We examined the involvement of GCS in the pathophysiology of SCZ. We resequenced the entire coding region and splice sites of GCS genes in 474 patients and 475 controls. We identified rare variants (A203V, S801N, and G825D in GLDC, and R253X in AMT) in patients with SCZ. Through plasma metabolomic analysis, we observed that 5-oxoproline, aspartate, and glutamate, known to affect NMDAR function, 49 were significantly elevated in patients with the rare variants in GCS genes. Moreover, Negative PANSS score symptoms and T1191  T277M  R410K  L429F  D465V  V512L   A5P  S175G   M394V  A408T  R410K   L429F T475I   V685M   S801N (2 cases)  G825D (2 cases)   D712E  V713M   S748W  M767V  R790Q  E1006D   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15 16  17  18  19  20  21  22  23 
G825D
Exonic deletions: exon1, exon1-2, exon1-3, exon1-16, exon1-17, exon1-25, exon3-4, exon3-8, exon3-9, exon3-21, exon3-22, exon5-8, exon8, exon9, exon12-15 Figure 2 . Rare variants observed in patients with schizophrenia (SCZ) and in controls (CT) in this study, and previously reported mutations for nonketotic hyperglycinemia (NKH) and other diseases, including autism spectrum disorder (ASD). A203V in one patient and S801N in two patients were located near the causative mutations of atypical NKH (A202V, A802V). G825D in GLDC, reported as a possible causative mutation in neural tube defect (NTD), was detected in two patients with SCZ.
© 2017 The Authors Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology aspartate were significantly inversely correlated in these patients. Genetic analysis focusing on potentially deleterious rare variants in GCS genes and exotic deletions did not reveal a significant difference in the total number of rare variants in patient and control groups. The clinical features of atypical NKH are similar to the psychiatric symptoms of SCZ in adults. As identification of the causal genetic mutation is necessary to diagnose atypical NKH, we also assessed whether atypical NKH was present in patients diagnosed with SCZ. Whilst sharing similar symptoms, the results did not support our hypothesis that NKH patients are included in SCZ. On the other hand, we detected the heterozygous R410K variant in one patient with SCZ and in one control, which is a relatively high frequency. R410K was previously reported as a causative mutation of NKH, 40 but despite intensive efforts in NKH mutation screening, this variant has not been reported in the Japanese population. Further examination is required to confirm that this variant is a causative mutation for NKH.
We did not observe a difference in the total number of rare variants between patients and controls. However, the variants of interest (GLDC A203V in one patient, GLDC S801N in two patients, GLDC G825D in two patients, and R253X in AMT in one patient) were detected in patients with SCZ. GLDC A203V and S801N were located near the causative mutations for atypical NKH (GLDC A202V, A802V), which present late-onset psychotic symptoms. 41, 42 The symptomatic features of atypical NKH patients with the A802V variant are cognitive impairment, not symptoms such as chorea and hypotonia often seen in other atypical NKH patients. 42 GLDC G825D, identified in two patients, was assumed to be the causative mutation for NTD decreasing the enzymatic activity of GLDC to 24%. 43 Interestingly, a previous epidemiological study showed shared risk of SCZ with NTD in terms of disturbance in folate metabolism. 50 ,51 Although we could not clarify the genetic contributions of these variants to SCZ in this study, these observations may lead to further studies using another large sample set.
We performed metabolome analysis using the plasma of patients with the GCS variants. Metabolome analysis revealed that plasma levels of 5-oxoproline, aspartate, and glutamate were markedly elevated in patients with the GCS genes variant, but the plasma level of glycine was not changed. Interestingly, the concentration of 5-oxoproline and aspartate have previously been reported to be altered in peripheral leukocytes of patients with SCZ. 52 Liu et al. reported that 5-oxoproline was significantly altered in patients with SCZ using 89 patients, including 46 first-episode and drug-naïve patients. 52 Regarding elevation of aspartate, we replicated the results reported by Liu et al. 52 Because of the extremely small sample size, the elevation of these metabolites as a specific phenomenon should be considered with caution. To overcome this problem, we referred to a previous report on metabolome analysis in patients with SCZ performed by the same method in two datasets composed of 38 controls versus 29 patients with SCZ in total (Dr Shinsuke Koike, pers. comm.). No patients or controls showed such a high elevation in these three metabolites, which suggests the possible involvement of the variants in GCS genes in this metabolomics profiling. Although we could not suggest the possible biological mechanisms, given the fact that GCS is involved in not only the metabolism of glycine but also that of D-serine, it might be possible that GCS had roles for catalyzing other amino acids directly or indirectly, which were derived from the variants.
Aspartate and glutamate affect NMDAR function and 5-oxoproline is converted to glutamate, 53 which might be involved in the symptoms of SCZ. This led us to evaluate the correlation between PANSS scores and the concentration of the three metabolites. The results showed a strong inverse correlation between aspartate levels and both the total Negative Symptoms score and the individual PANSS scores of the negative symptoms in the patients. Improvement of the negative symptoms of SCZ treated by clozapine was associated with increased plasma aspartate concentrations in a previous study.
54 This is consistent with our results, which show that higher aspartate in plasma is related to milder negative symptoms of SCZ. Negative symptoms are extremely treatmentresistant and prevent the social recovery of patients. Aspartate might be a therapeutic target for alleviating the negative symptoms of SCZ.
There are several limitations in this study that should be mentioned. First, our sample size was relatively small and lacked the statistical power to detect an association between very rare variants in GCS genes and SCZ. According to the power analysis, we have 80% of statistical power to detect the rare variants (MAF = 0.5%) with an effect size greater than 6. However, more than 1500 patients with SCZ would be needed to detect the rare variants if we were to examine the association between rare variants with effect size greater than 3.
55 Second, the sample size for the metabolome analysis was extremely small. Confirmation of the metabolites by using another method is necessary. Further study using a larger sample size and an additional SCZ group without the rare variants in GCS is required. Third, we did not examine exonic deletions in GCS genes other than GLDC. Fourth, we were able to detect the concentration of Lserine in this study; however, we were unable to measure the concentration of D-serine, which might possibly be affected by the variants of the GCS genes.
In conclusion, this study suggests that GCS rare variants might possibly contribute to the pathophysiology of SCZ by affecting negative symptoms through elevation of aspartate, the mechanism of which should be examined in the future. 
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